A Phase II Study of IL-18 in Melanoma Patients
A Phase II Study of IL-18 in Melanoma Patients
This Phase II study is designed to evaluate the anti-tumor activity of three dose groups of SB-485232 (0.01, 0.1, and 1.0 mg/kg/day) administered intravenously as a single agent in subjects with previously untreated metastatic melanoma.
Inclusion criteria:
Exclusion criteria: